Cancer nanomedicines: oversold or underappreciated?

Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin

(2016) Grant H. Petersen et al.   JOURNAL OF CONTROLLED RELEASE

Antibody–drug conjugates for cancer therapy

(2016) Anish Thomas et al.   LANCET ONCOLOGY

Gulp1 is associated with the pharmacokinetics of PEGylated liposomal doxorubicin (PLD) in inbred mouse strains

(2016) Gina Song et al.   Nanomedicine-Nanotechnology Biology and Medicine

Mechanism of hard-nanomaterial clearance by the liver

(2016) Kim M. Tsoi et al.   NATURE MATERIALS

Erratum: Cancer nanomedicine: is targeting our target?

(2016) Twan Lammers et al.   Nature Reviews Materials

Analysis of nanoparticle delivery to tumours

(2016) Stefan Wilhelm et al.   Nature Reviews Materials

Lessons in simplicity that should shape the future of drug delivery

(2015) Koen Raemdonck et al.   NATURE BIOTECHNOLOGY

Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth In Vivo

(2015) Jan Kroon et al.   PROSTATE

Extracellular vesicles as drug delivery systems: Lessons from the liposome field

(2014) Roy van der Meel et al.   JOURNAL OF CONTROLLED RELEASE

Remote loading of preencapsulated drugs into stealth liposomes

(2014) Surojit Sur et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status

(2013) Roy van der Meel et al.   ADVANCED DRUG DELIVERY REVIEWS

Analysis on the current status of targeted drug delivery to tumors

(2012) Il Keun Kwon et al.   JOURNAL OF CONTROLLED RELEASE